Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
June 1, 2020

Genentech gets FDA approval for Tecentriq, Avastin combo for HCC

Genentech has secured approval from the US Food and Drug Administration (FDA) for Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) for the treatment of unresectable or metastatic hepatocellular carcinoma (HCC).

Genentech announces FDA approval for its Tecentriq, Avastin combination for unresectable or metastatic HCC. (Credit: F. Hoffmann-La Roche Ltd)